Overall, BMP9 is closely associated with obesity, mainly reducing the bodyweight of decreasing WAT, enhancing the activity of BAT, and increasing BAT as well as “browning.” It may be a method for the treatment of obesity and obesity-related complications such as NAFLD as presented in Figure 2. The gene discussed is GDF2; the disease is metabolic dysfunction-associated steatotic liver disease.